Research programme: scavenger mRNA decapping enzyme inhibitors - FSMA/Repligen

Drug Profile

Research programme: scavenger mRNA decapping enzyme inhibitors - FSMA/Repligen

Alternative Names: D 157495; Spinal muscular atrophy (SMA) programme - Repligen/Pfizer

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Families of SMA
  • Developer Families of SMA; Repligen Corporation
  • Class Quinazolines
  • Mechanism of Action Survival of motor neuron 1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Spinal muscular atrophy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy in USA
  • 15 Mar 2015 Repligen has patent protection for spinal muscular atrophy programme in USA (Repligen Form 10-K filed in March 2015)
  • 03 Jan 2013 Repligen's spinal muscular atrophy programme (including RG 3039 and backup compounds) sub-licensed to Pfizer worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top